Rheumatologists ‘face rituximab dilemma’ with endemic COVID-19
Yet another study shows that, alone among immunosuppressants, the monoclonal antibody is linked to increased mortality among the infected
Optimal strategies need to be developed for patients relying on rituximab in a world where COVID-19 becomes endemic, two Australian rheumatologists warn.
Just as rituximab is being shown to have potential utility across multiple diseases, evidence is accumulating that it’s associated with worsening severity of COVID-19 illness and increased deaths, they write in an editorial in The Lancet Rheumatology.
